Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siwen Hu-Lieskovan

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
The Journal of Experimental Medicine|December 2, 2016
What does PD-L1 positive or negative mean?Antoni Ribas, Siwen Hu-Lieskovan
Cancer Journal (Sudbury, Mass.)|January 24, 2017
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a BackboneSiwen Hu-Lieskovan, Antoni Ribas
Drugs|February 26, 2020
Mechanisms of Resistance to PD-1 Checkpoint BlockadeJustin C Moser, Siwen Hu-Lieskovan
Seminars in Immunology|February 11, 2016
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Lidia Robert, Antoni Ribas, Siwen Hu-Lieskovan
The Lancet. Oncology|September 30, 2019
Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?Sumanta Pal, Siwen Hu-Lieskovan, Neeraj Agarwal
Cancer Cell|June 10, 2015
Excluding T Cells: Is β-Catenin the Full Story?Siwen Hu-Lieskovan, Blanca Homet Moreno, Antoni Ribas
Cancer Journal (Sudbury, Mass.)|January 24, 2018
Mechanisms of Resistance to PD-1 and PD-L1 BlockadeTheodore S Nowicki, Siwen Hu-Lieskovan, Antoni Ribas
Melanoma Research|December 20, 2024
Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literatureJohn Marsiglio, Jordan McPherson, Matthew Wahl, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|July 17, 2023
Immune Resistance Mechanisms and the Road to Personalized ImmunotherapyMiles Piper, Harriet Kluger, Eytan Ruppin, et al.
Cell|February 11, 2017
Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyPadmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
The Journal of Experimental Medicine|December 2, 2016
What does PD-L1 positive or negative mean?Antoni Ribas, Siwen Hu-Lieskovan
Cancer Journal (Sudbury, Mass.)|January 24, 2017
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a BackboneSiwen Hu-Lieskovan, Antoni Ribas
Drugs|February 26, 2020
Mechanisms of Resistance to PD-1 Checkpoint BlockadeJustin C Moser, Siwen Hu-Lieskovan
Seminars in Immunology|February 11, 2016
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Lidia Robert, Antoni Ribas, Siwen Hu-Lieskovan
The Lancet. Oncology|September 30, 2019
Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?Sumanta Pal, Siwen Hu-Lieskovan, Neeraj Agarwal
Cancer Cell|June 10, 2015
Excluding T Cells: Is β-Catenin the Full Story?Siwen Hu-Lieskovan, Blanca Homet Moreno, Antoni Ribas
Cancer Journal (Sudbury, Mass.)|January 24, 2018
Mechanisms of Resistance to PD-1 and PD-L1 BlockadeTheodore S Nowicki, Siwen Hu-Lieskovan, Antoni Ribas
Melanoma Research|December 20, 2024
Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literatureJohn Marsiglio, Jordan McPherson, Matthew Wahl, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|July 17, 2023
Immune Resistance Mechanisms and the Road to Personalized ImmunotherapyMiles Piper, Harriet Kluger, Eytan Ruppin, et al.
Cell|February 11, 2017
Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyPadmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, et al.
Pageof 9